Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
0 rating

PDE5 Inhibitors

Galiè N, Brundage BH, Ghofrani HA et al.; Pulmonary Arterial Hypertension & Responseto Tadalafil (PHIRST) Study Group.

University of Bologna, Bologna, Italy.

Circulation 2009;119:2894–903.

Editor’s note: Current treatments for pulmonary arterial hypertension (PAH) work to improve patients’ symptoms, exercise capacity, and clinical outcome, but are limited by inconvenient delivery systems, requirements for laboratory monitoring, and dosing schedules that are too frequent. Consequently, there is a need to find a convenient, yet safe and effective, oral, once-daily therapy for the treatment of PAH. Previous studies have shown that the phosphodiesterase type 5 inhibitor sildenafil improves exercise capacity and hemodynamic parameters in patients with PAH.

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles